Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Howard Hughes Medical Institute to limit eligible universities for Investigator Program in bid to spread the wealth
The next round of competition, slated for late 2025, will have a new focus, according to an HHMI spokesperson.
Howard Hughes Medical Institute to limit eligible universities for Investigator Program in bid to spread the wealth
The next round of competition, slated for late 2025, will have a new focus, according to an HHMI spokesperson.
An eye for science: Q&A with Bryan W. Jones
The researcher explains how the beauty of the retina drew him into the vision field and why photography reminds him of the value of that work.
An eye for science: Q&A with Bryan W. Jones
The researcher explains how the beauty of the retina drew him into the vision field and why photography reminds him of the value of that work.
Extra Y chromosomes are linked to autism
Data from people with more or fewer than two sex chromosomes could help answer questions around genetic protection and vulnerability.
Extra Y chromosomes are linked to autism
Data from people with more or fewer than two sex chromosomes could help answer questions around genetic protection and vulnerability.